The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Druggability Indices for Protein Targets Derived from NMR-Based Screening Data
Abstract
An analysis of heteronuclear-NMR-based screening data is used to derive relationships between the ability of small molecules to bind to a protein and various parameters that describe the protein binding site. It is found that a simple model including terms for polar and apolar surface area, surface complexity, and pocket dimensions accurately predicts the experimental screening hit rates with an R(2) of 0.72, an adjusted R(2) of 0.65, and a leave-one-out Q(2) of 0.56. Application of the model to predict the druggability of protein targets not used in the training set correctly classified 94% of the proteins for which high-affinity, noncovalent, druglike leads have been reported. In addition to understanding the pocket characteristics that contribute to high-affinity binding, the relationships that have been defined allow for quantitative comparative analyses of protein binding sites for use in target assessment and validation, virtual ligand screening, and structure-based drug design.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Numerical recipes: the art of scientific computing
Press, W. H., Flannery, B. P., Teukolsky, S. A., Vetterling, W. T., & Chipperfield, J. R. (1987) · Analytica Chimica Acta · doi:10.1016/s0003-2670(00)82860-3 · Cited by 3,304
Discovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,041
Self-citationAnatomy of hot spots in protein interfaces
Bogan, A. A., & Thorn, K. S. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1843 · Cited by 1,988
A simple physical model for binding energy hot spots in protein–protein complexes
Kortemme, T., & Baker, D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202485799 · Cited by 804
Is There a Difference between Leads and Drugs? A Historical Perspective
Oprea, T. I., Davis, A. M., Teague, S. J., & Leeson, P. D. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci010366a · Cited by 769
Unraveling hot spots in binding interfaces: progress and challenges
DeLano, W. L. (2002) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(02)00283-x · Cited by 767
Fast prediction and visualization of protein binding pockets with PASS
Brady, G. P., & Stouten, P. F. W. (2000) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1008124202956 · Cited by 531
Identification of Protein–Protein Interaction Sites from Docking Energy Landscapes
Fernández-Recio, J., Totrov, M., & Abagyan, R. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.10.069 · Cited by 274
Peters, K. P., Fauck, J., & Frömmel, C. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0077 · Cited by 243
Discovering High-Affinity Ligands for Proteins
Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1997) · Science · doi:10.1126/science.278.5337.497 · Cited by 236
Self-citation
Cited by
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Reaching for high-hanging fruit in drug discovery at protein–protein interfaces
Wells, J. A., & McClendon, C. L. (2007) · Nature · doi:10.1038/nature06526 · Cited by 1,960
Small molecules, big targets: drug discovery faces the protein–protein interaction challenge
Scott, D. E., Bayly, A. R., Abell, C., & Skidmore, J. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.29 · Cited by 1,137
A decade of fragment-based drug design: strategic advances and lessons learned
Hajduk, P. J., & Greer, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2220 · Cited by 1,064
Self-citationTwenty years on: the impact of fragments on drug discovery
Erlanson, D. A., Fesik, S. W., Hubbard, R. E., Jahnke, W., & Jhoti, H. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.109 · Cited by 1,000
Self-citationStructure-based maximal affinity model predicts small-molecule druggability
Cheng, A. C., Coleman, R. G., Smyth, K. T., Cao, Q., Soulard, P., Caffrey, D. R., Salzberg, A. C., & Huang, E. S. (2007) · Nature Biotechnology · doi:10.1038/nbt1273 · Cited by 695
Virtual ligand screening: strategies, perspectives and limitations
Klebe, G. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.05.012 · Cited by 664
Kozakov, D., Grove, L. E., Hall, D. R., Bohnuud, T., Mottarella, S. E., Luo, L., Xia, B., Beglov, D., & Vajda, S. (2015) · Nature Protocols · doi:10.1038/nprot.2015.043 · Cited by 648
Recent Developments in Fragment-Based Drug Discovery
Congreve, M., Chessari, G., Tisi, D., & Woodhead, A. J. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8000373 · Cited by 611
Discovery of small molecule cancer drugs: Successes, challenges and opportunities
Hoelder, S., Clarke, P. A., & Workman, P. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.02.004 · Cited by 587
Combining Global and Local Measures for Structure-Based Druggability Predictions
Volkamer, A., Kuhn, D., Grombacher, T., Rippmann, F., & Rarey, M. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci200454v · Cited by 496
Brenke, R., Kozakov, D., Chuang, G.-Y., Beglov, D., Hall, D., Landon, M. R., Mattos, C., & Vajda, S. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp036 · Cited by 455
A detergent-based assay for the detection of promiscuous inhibitors
Feng, B. Y., & Shoichet, B. K. (2006) · Nature Protocols · doi:10.1038/nprot.2006.77 · Cited by 429
Perspectives on NMR in drug discovery: a technique comes of age
Pellecchia, M., Bertini, I., Cowburn, D., Dalvit, C., Giralt, E., Jahnke, W., James, T. L., Homans, S. W., Kessler, H., Luchinat, C., et al. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2606 · Cited by 414
Villar, E. A., Beglov, D., Chennamadhavuni, S., Porco, J. A., Kozakov, D., Vajda, S., & Whitty, A. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1584 · Cited by 400
Fragment-based lead discovery: leads by design
Carr, R. A. E., Congreve, M., Murray, C. W., & Rees, D. C. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03511-7 · Cited by 343
Binding MOAD (Mother Of All Databases)
Hu, L., Benson, M. L., Smith, R. D., Lerner, M. G., & Carlson, H. A. (2005) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.20512 · Cited by 328
Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening
Resnick, E., Bradley, A., Gan, J., Douangamath, A., Krojer, T., Sethi, R., Geurink, P. P., Aimon, A., Amitai, G., Bellini, D., et al. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b02822 · Cited by 335
How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets
Doak, B. C., Zheng, J., Dobritzsch, D., & Kihlberg, J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01286 · Cited by 335
Zhang, Z., Li, Y., Lin, B., Schroeder, M., & Huang, B. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr331 · Cited by 332
Schmidtke, P., & Barril, X. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100574m · Cited by 331
Predicting druggable binding sites at the protein–protein interface
Fuller, J. C., Burgoyne, N. J., & Jackson, R. M. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.10.009 · Cited by 310
Analyzing the Topology of Active Sites: On the Prediction of Pockets and Subpockets
Volkamer, A., Griewel, A., Grombacher, T., & Rarey, M. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci100241y · Cited by 300
A practical view of ‘druggability’
Keller, T. H., Pichota, A., & Yin, Z. (2006) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2006.06.014 · Cited by 295
FTSite: high accuracy detection of ligand binding sites on unbound protein structures
Ngan, C.-H., Hall, D. R., Zerbe, B., Grove, L. E., Kozakov, D., & Vajda, S. (2012) · Bioinformatics · doi:10.1093/bioinformatics/btr651 · Cited by 292
Predicting protein druggability
Hajduk, P. J., Huth, J. R., & Tse, C. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03624-x · Cited by 289
Self-citationLigand efficiency indices for effective drug discovery
Abad-Zapatero, C. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.4.469 · Cited by 279
Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery
Pérot, S., Sperandio, O., Miteva, M. A., Camproux, A.-C., & Villoutreix, B. O. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.05.015 · Cited by 276
Screening in a spirit haunted world
Shoichet, B. K. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.05.014 · Cited by 276
Fragment-Based Drug Design: How Big Is Too Big?
Hajduk, P. J. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060511h · Cited by 265
Self-citationThe role of quantum mechanics in structure-based drug design
Raha, K., Peters, M. B., Wang, B., Yu, N., Wollacott, A. M., Westerhoff, L. M., & Merz, K. M. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.07.006 · Cited by 252
Structural Biology and Drug Discovery of Difficult Targets: The Limits of Ligandability
Surade, S., & Blundell, T. L. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.013 · Cited by 230
State-of-the-art strategies for targeting protein–protein interactions by small-molecule inhibitors
Sheng, C., Dong, G., Miao, Z., Zhang, W., & Wang, W. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00252d · Cited by 165
Fragment-Based Lead Discovery and Design
Joseph-McCarthy, D., Campbell, A. J., Kern, G., & Moustakas, D. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci400731w · Cited by 129
Targeting Protein–Protein Interactions and Fragment-Based Drug Discovery
Valkov, E., Sharpe, T., Marsh, M., Greive, S., & Hyvönen, M. (2011) · Topics in Current Chemistry · doi:10.1007/128_2011_265 · Cited by 107
Golden, M. S., Cote, S. M., Sayeg, M., Zerbe, B. S., Villar, E. A., Beglov, D., Sazinsky, S. L., Georgiadis, R. M., Vajda, S., Kozakov, D., et al. (2013) · Journal of the American Chemical Society · doi:10.1021/ja400914z · Cited by 47
Bohnuud, T., Kozakov, D., & Vajda, S. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003872 · Cited by 27
Elucidating the druggability of the human proteome with eFindSite
Kana, O., & Brylinski, M. (2019) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-019-00197-w · Cited by 27
Protein-inhibitor interaction studies using NMR
Ishima, R. (2015) · Applications of NMR Spectroscopy · doi:10.2174/9781608059621115010007 · Cited by 13
Assessing the binding properties of CASP14 targets and models
Egbert, M., Ghani, U., Ashizawa, R., Kotelnikov, S., Nguyen, T., Desta, I., Hashemi, N., Padhorny, D., Kozakov, D., & Vajda, S. (2021) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.26209 · Cited by 10
Protein-Protein Interactions as Drug Targets
Wendt, M. D. (2012) · Topics in Medicinal Chemistry · doi:10.1007/978-3-642-28965-1_1 · Cited by 9
Metadata
- Authors
- Hajduk, P. J., Huth, J. R., & Fesik, S. W.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2005-02-24
- Volume
- 48
- Issue
- 7
- Pages
- 2518-2525
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1979598348
- Cited by
- 522
- References
- 23
- FWCI
- 30.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.